]>
IRCT20201126049497N1 IRCT 2021-11-09 Birjand University of Medical Sciences Comparison the effect of 3 day with 7 day GNRH-antagonist in prevention of ovarian hyperstimulation syndrome(OHSS) Comparison the effect of 3 days with 7 days GNRH-antagonist in prevention of ovarian hyperstimulation syndrome(OHSS) in women undergoing assisted reproductive technology (ART) 2021-10-18 anticipated 40 Complete https://irct.ir/trial/59414 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study, due to the different time of consumption, it is not possible to blind the subject, but the researcher who examines the outcome will be blind.Of course, it should be noted that the study outcome is such that non-blindness does not affect the outcome (it is an objective outcome). 2 Ovarian hyperstimulation syndrome. Intervention 1: Intervention group: drug(cetrotide) for 3 days. Intervention 2: Intervention group:drug(cetrotide) for 7 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information
public vajihe hazari
No 16, soraya avey, Tohid St, Birjand
Birjand Iran (Islamic Republic of) 9718876655 +98 56 3243 6691 vajihehazari@bums.ac.ir Birjand University of Medical Sciences scientific vajihe hazari
No 16, soraya avey, Tohid St, Birjand
birjand Iran (Islamic Republic of) 9718877655 +98 56 3243 6691 vajihehazari@bums.ac.ir Birjand University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Having informed consent to enter the study. The possibility of useful intervention on individuals. Age between 18 and 40 years. The person is at risk for OHSS syndrome (for example, the number of recovered eggs is more than 15 or serum estradiol more than 3000 pg / ml Any person who does not meet any of the exclusion criteria will be included in the study if satisfied 18 years 40 years Female Dissatisfaction to enter the study Age less than 18 years or more than 40 years Any disease that interferes with the intended intervention. Patient with diabetes / hemophilia or coagulation disorde Patients with pulmonary fibrosis, swelling or inflammation around the heart or lungs, high blood pressure, liver disease, heart valve disease, or allergy to cabergoline or ergot derivatives Use of drugs that affect the development of OHSS syndrome (calcium gluconate / metformin / letrozole / other GNRH-ant antagonists) Pregnancy during the study cycle Contraindications that are considered by a specialist and are not included in the test. N98.1 Hyperstimulation of ovaries Treatment - Drugs Treatment - Drugs Intervention group: drug(cetrotide) for 3 days Intervention group:drug(cetrotide) for 7 days Ovarian hyperstimulation syndrome. Timepoint: One week after OPU. Method of measurement: Clinical and laboratory evaluation and sonography. Birjand University of Medical Sciences Approved 2021-10-09 Ethics Committee of Birjand University of Medical Sciences Ghaffari Street, Birjand Birjand South Khorasan Iran (Islamic Republic of)